Beta Drugs Ltd

- Current expansions have been mostly funded through internal sources; out of Rs. 78 crore invested in three companies, only Rs. 1 crore has been utilized out of a Rs. 2 crore loan. - The company aims to avoid taking substantial new loans and has enough reserves for planned expansions. - Future CAPEX for injectable line expansion (estimated Rs. 30-35 crore) will be met without major debt, maintaining the company’s current financial status. - No explicit mention of planned equity fundraising in the disclosed content. - The focus remains on organic growth and selective M&A opportunities mainly related to Oncology, but no clear plans for fundraising through equity or debt were discussed.

- Current expansion already incurred about 50%-60% of planned capex, mostly through internal sources with minimal loans (~Rs. 1 Cr utilized out of Rs. 2 Cr loan). - Existing capacity can support sales up to Rs. 220-240 Cr without major new investment. - Further capex for product registration and formulation expected in the next phase. - Once sales reach Rs. 260-270 Cr, a new injectable manufacturing line (lyophilized) will be added; land and space available for 2-3 more blocks. - Estimated investment for injectable line expansion is Rs. 30-35 Cr, funded mainly from reserves without significant new loans. - Discussions underway for regulated market expansions, including EU market entry via MA acquisition. - M&A strategy focused on opportunities linked to Oncology divisions; engagement with Deloitte and pharma-specific contacts to explore acquisitions. - R&D capex increasing towards product development, aiming for 5-7 new molecule developments per year.

- The company targets a 30% to 35% annual growth rate in sales/revenue over the next 3 to 4 years. - For FY22, the expected revenue is around Rs. 200 crore, with the second half projected to outperform the first half. - The current capacity can support sales growth up to approximately Rs. 220 crore to Rs. 240 crore without major new CAPEX. - Beyond Rs. 260-270 crore sales, a modest CAPEX of Rs. 30-35 crore is planned for new injectable production lines to sustain growth. - International market expansion is underway, targeting 22 additional countries and focusing on Latin America, CIS, Southeast Asia, and Africa, with substantial growth expected from 2023 onwards. - The company plans to launch 20-25 molecules in upcoming years, with emphasis on oncology segments like hematology, lung, breast, and prostate cancers, driving future volume increases. - Export revenue is expected to contribute 30-35%, alongside growing domestic branded sales.

- Management expects EBITDA margin to improve by 100 to 150 basis points annually over the next 2-3 years (Page 10). - The company targets 30% to 35% annual sales growth for the next 3-4 years, driven by branded formulations, exports, and API segments (Pages 5, 9, 10). - Second half of the financial year is expected to be better than the first half, supporting earnings growth (Page 3). - Margin expansion is supported by increased own branded formulations and export revenues (Pages 9, 10). - Cost advantage due to in-house API development and focus on oncology products contribute to profitability (Page 3). - EBITDA margin expansion and revenue growth together indicate strong outlook for operating earnings and profits.

- The company has a healthy order book with institutional orders lined up, contributing to expected robust growth in the current financial year (Page 7). - Orders from corporate hospitals and private markets are increasing steadily, supporting sales growth in branded formulations (Page 7-8). - Exports registrations are underway with regulatory filings and inspections expected soon, which will further strengthen order inflows from export markets (Page 5, 13). - CRAM (Contract Research and Manufacturing) business has steady long-term customer relationships with recurring annual agreements and no reported order cancellations (Page 9). - Expansion plans are linked to capacity utilization, with new production lines and blocks being added to meet rising demand and to onboard new orders (Pages 14-15). - Overall, order book is set to support a targeted 30%-35% growth annually over the next few years (Page 5, 9).